our team

Dr Rudkin has a strong background in antibody discovery and preclinical development, with a proven track record in advancing innovative treatments from early-stage discovery to preclinical proof-of-concept. Dr Rudkin’s career spans academia, industry, and entrepreneurship.

She has held roles as a Principal Investigator at the University of Aberdeen, an Independent Biotech Advisor in Paris, and a Research Scientist within Pfizer’s Global Biotherapeutic Technologies Division.

She earned her Ph.D. in Microbiology from the University of Aberdeen in collaboration with Pfizer Inc. and has further honed her leadership and business acumen through entrepreneurial training at MIT and a Royal Society of Edinburgh Enterprise Fellowship.

Dr Rudkin has led mycoBiologics since its inception and is an inventor on the granted and filed patents underpinning the core technology of the company.

Under her leadership, the company has successfully secured over £1M in non-dilutive funding from Scottish Enterprise and a Wellcome Innovator Award to advance anti-infective mAb therapeutics towards first-in-human trials.

Mr Thomson is Chief Executive Officer and co-founder at Pneumagen. His background is in infectious disease research and development.

He was previously at SingVax, in Singapore, as CEO, and Microscience Ltd as Business Development Director.

Douglas currently sits on the board of Omideon, a St. Andrews based biotech company focused on the development of novel treatments for cancer; he is a non-executive director of EnteroBiotix, a microbiome therapeutics platform and product company and is a Venture Partner with the KAMRA fund, which is focused on infectious disease.

Neil Gow is Professor of Microbiology and Medical Mycology at the University of Exeter and works in the MRC Centre for medical Mycology – Europe’s largest bespoke centre for medical mycology research.  He was the previous Deputy Vice Chancellor for Research and Impact at the University of Exeter where he led the research vision and strategy for the university, but he is now engaged full time in research.

He trained as an infectious disease microbiologist at the University of Edinburgh, the University of Aberdeen, and The University of Denver. His research group focuses on the structure and function of fungal cell walls, which are crucial for maintaining cell integrity and influencing how fungi interact with their environment and the immune system, and on antifungal drugs and fungal antimicrobial resistance (fAMR).

He has served and chaired numerous research funding councils (Wellcome, Royal Society (URF), Academy of Medical Sciences (Springboard); UKRI (epidemic preparedness); DFG -Germany; REF (Research Excellence Framework); FAILSAFE (fungal AMR in LMIC) and has acted as President of five international societies of mycology and microbiology: The British Mycological Society, the International Society for Human and Animal Mycology (ISHAM), The Microbiology Society, the British Society for Medical Mycology (BSMM) and the European Confederation of medical Mycology (ECMM) – for which he is the current president.

Professor Vyas is the Roy and Diana Vagelos Professor of Medicine at Columbia Vagelos College of Physicians and Surgeons, Associate Dean for Academic Innovation, and Director of Physician Scientist Programs at the Vagelos Institute for Biomedical Research Education.

He is also an Associate Member of the Broad Institute in Cambridge, MA. He attended Baylor College of Medicine in their Medical Scientist Training Program, where Jay received his PhD in 1994 and MD in 1996. Upon completion of his MD, Jay moved to Boston to complete his medical internship and residency in internal medicine in the Department of Medicine at the Massachusetts General Hospital/Harvard Medical School. He completed his fellowship in Infectious Diseases in the Massachusetts General Hospital/Brigham and Women’s Hospital program.

Following a period of post-doctoral research training in the Harvard Department of Pathology and Whitehead Institute for Biomedical Research, Professor Vyas joined the faculty of the Harvard Medical School and the Massachusetts General Hospital in 2007 and was promoted to Professor of Medicine at Harvard Medical School in 2024.

He moved to Columbia University in October 2024. Professor Vyas is internationally recognized for his work in fungal immunology, investigating how our body responds to fungal pathogens. His work has elucidated the critical innate immune signalling pathways operant in macrophages, dendritic cells, and lung epithelial cells.